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Angiogenesis is the growth of new blood vessels that plays an essential role in development 
and wound healing as well as during coronary revascularization, which is necessary to repair 
tissues following a myocardial ischemic event. Arteriogenesis is the increase in diameter and wall 
thickness of pre-existing blood vessels to provide blood flow to otherwise deprived tissue. This 
can be beneficial through widening collateral vessels when occlusions and ischemia occur. PLGF 
is a multifunctional angiogenic and arteriogenic cytokine that is secreted as a compensatory 
response following vascular occlusion. PLGF is unique in that it drives both physiological 
(arteriogenesis) and pathological (atherosclerosis) processes. Atherosclerosis is a gradual process 
whereby arteries become increasingly narrow due to the presence of fatty plaques in the arterial 
wall that protrude into the vessel space and compromise blood flow to distal regions. PLGF 
contributes to early progression of atherosclerosis and serves as a clinical biomarker for 
cardiovascular disease. Hyperglycemia is a well-established risk factor for cardiovascular disease 
due to glucose-driven damage to the endothelial cells lining the vessel wall, as well as increased 
osmolarity in the vessel. H2S is endogenously produced in the human body by the enzyme 
cystathionine gamma lyase (CSE) in vascular cells. H2S has been shown to be pro-angiogenic, 
anti-inflammatory, and vasodilatory. The effect of H2S on arteriogenesis, as well as combating 
atherosclerosis is unknown. Since low levels of hydrogen sulfide (H2S) have recently been shown 
to be protective to the cardiovascular system, we hypothesized that treatment of human vascular 
cells with H2S would increase secretion of the pro-arteriogenic cytokine, PLGF. Based on 
conclusions from our first hypothesis, we further hypothesized that hyperglycemia would increase 
secretion of PLGF and that H2S treatment would reverse this effect. We found that H2S decreased 
PLGF secretion at 6 hours post treatment in human vascular smooth muscle and endothelial cells 
under basal conditions. In addition, we found that hyperosmolarity-induced PLGF secretion was 
reversed by H2S treatment.  We conclude that H2S treatment reduces the secretion of PLGF and 
therefore protects vascular cells from a PLGF-driven pro-atherogenic environment. Further studies 





About 600,000 people die from heart disease every year, with 385,000 of those deaths resulting 
from coronary artery disease.4 Oklahoma has one of the highest rates of cardiovascular disease. 
There are many different drug therapies available to treat cardiovascular disease through different 
mechanisms including antiplatelet drugs, anticoagulants, beta blockers, and nitric oxide (NO) 
donors/vasodilators.2 Recent studies to better understand cardiovascular disease and potential 
treatments have focused on important signaling molecules produced by the vessel wall, such as 
the well-known vasodilator NO, which targets angiogenic and arteriogenic pathways. Hydrogen 
sulfide (H2S) has long been recognized as a toxic environmental gas (similar to the initial 
understanding of NO) that inhibits the final step in the mitochondrial electron transport chain, 
which blocks ATP production.5 However, recent evidence shows that H2S is endogenously 
produced at low concentrations by our blood vessels and exerts a number of beneficial properties 
including anti-inflammatory, anti-oxidative, vaso-relaxant and pro-angiogenic actions.1  
Angiogenesis is the growth of new blood vessels that plays an essential role in development 
and wound healing as well as during coronary revascularization, which is necessary to repair 
tissues following a myocardial ischemic event. Angiogenesis can be pathological in the 
development of cancer tumors and plaques, but also beneficial in wound healing, embryogenesis, 
development, and ischemic damage. The angiogenic process promotes important compensatory 
and repair mechanisms in cardiovascular disease.7 Arteriogenesis is the increase in diameter and 
wall thickness of pre-existing blood vessels to provide blood flow to otherwise deprived tissue. 
This can be beneficial through widening collateral vessels when occlusions and ischemia occur.9 
Placental Growth Factor (PLGF) is a member of the Vascular Endothelial Growth Factor 
(VEGF) family that was first discovered in the placenta as a critical growth factor, but was later 
found to be important in the cardiovascular system. VEGF itself is a cytokine involved in the 
growth of vascular endothelial cells and is important in both angiogenesis and arteriogenesis. 
PLGF is a multifunctional angiogenic and arteriogenic cytokine that is secreted as a compensatory 
response following vascular occlusion. It has been shown in skeletal muscle, post ligation of the 
femoral artery, to drive the expansion of collateral vessels. While VEGF is also an important 
cytokine for arteriogenesis, PLGF has been shown to be more robust in its ability to drive 
arteriogenesis. VEGF has been shown to be essential for life in mice, while PLGF deficiency is 
not lethal. While this makes PLGF redundant in its ability to drive angiogenesis and arteriogenesis, 
PLGF is unique in that it drives both physiological (arteriogenesis) and pathological 
(atherosclerosis) processes. The mechanism whereby this switch occurs from physiological to 
pathological is an area of active investigation. Therefore, PLGF is a target of interest for 
cardiovascular disease treatments.11,7  
Blood flow creates shear stress that acts on the vessel wall, which serves as a signal for 
arteriogenesis. In previous collaborative studies, our laboratory with P. Lloyd mimicked shear 
stress on the coronary vessel wall and found that exposure to shear stress drives an arteriogenic 
response, resulting in an increase in PLGF secretion and an increase in cystathionine gamma lyase 
(CSE) gene expression in coronary endothelial cells (ECs). This correlation between CSE gene 
expression in ECs and the increase in PLGF secretion suggested that H2S plays a role in the process 
of arteriogenesis. 
Despite several benefits of angiogenesis and arteriogenesis, these processes can be 
pathological, such as in the vascularization of tumors and in atherosclerotic plaque progression, 
which enhances lesion growth and coronary arterial occlusion.4 Atherosclerosis is a gradual 
process whereby arteries become increasingly narrow due to the presence of fatty plaques in the 
arterial wall that protrude into the vessel space and compromise blood flow to distal regions.4 
PLGF contributes to early progression of atherosclerosis and serves as a clinical biomarker for 
cardiovascular disease. Cardiovascular disease is multifaceted with many risk factors that can 
contribute to progression of the disease. Hyperglycemia is a well-established risk factor for 
atherosclerosis and cardiovascular disease due to glucose-driven damage to the endothelial cells 
lining the vessel wall, as well as increased osmolarity in the vessel.4 Hyperglycemia affects about 
10 percent of Americans and more than 13 percent of Oklahomans; thus there is a need for different 
therapeutics to treat hyperglycemia.8  
At high concentrations, H2S is a flammable, toxic, odorous gas that is formed through the 
breakdown of organic matter and waste materials.5 This gas can have detrimental effects on human 
health when exposed to large amounts, possibly resulting in death.4 However, H2S is endogenously 
produced in the human body by the enzyme cystathionine gamma lyase (CSE) in vascular cells 
and is the byproduct of cysteine metabolism. H2S, at low concentrations, has been shown to be 
pro-angiogenic, anti-inflammatory, and vasodilatory. It is also thought to be anti-atherogenic. Due 
to these qualities, H2S donating drugs are in pre-clinical and clinical trials. For example H2S 
donating nonsteroidal anti-inflammatory drugs (NSAIDs) are in clinical trials to reduce the 
detrimental effects NSAIDs have on the gastrointestinal system after long periods of use.3 
However, the effect of H2S on arteriogenesis, as well as combating atherosclerosis is unknown. 
Since low levels of H2S have recently been shown to be protective to the cardiovascular system, 
we hypothesized that treatment of human vascular cells with H2S would increase secretion of the 
pro-arteriogenic cytokine, PLGF. Based on conclusions from our first hypothesis, we further 
hypothesized that hyperglycemia would increase secretion of PLGF and that H2S treatment would 
reverse this effect.  The objectives were to (i) expose vascular cells to H2S and a H2S-donating 
drug (S-diclofenac), (ii) measure PLGF protein secretion and CSE gene expression in H2S-treated 
versus untreated cells, (iii) treat human endothelial cells with hyperglycemic conditions in the 
presence or absence of H2S and measure PLGF secretion, and (iv) measure PLGF protein secretion 




 Coronary artery smooth muscle cells (CASMC) were obtained from a 51 year old male 
donor and purchased from Lonza (Wakersville, MD). CASMC were cultured in 6-well plates in a 
CO2 incubator (37° C, 5% CO2) with smooth muscle cell (SmGM) medium until ~85% confluent.  
CASMC medium was supplemented with 5% fetal bovine serum (FBS) and growth factors to 
promote healthy, robust growth. Cells were serum starved for 48 hours by reducing the FBS to 1% 
in order to synchronize cell population growth prior to treatment.  This procedure was repeated 3 
times in duplicate (n=6). Pooled human umbilical vein endothelial cells (HUVEC) were also 
purchased from Lonza (Walkersville, MD, USA) and grown in 6-well plates at 37°C in 5% CO2 
until 85% confluent with EBM-2 medium. HUVEC medium was supplemented with growth 
factors and 2.5% FBS (Lonza).  Cells were serum starved for 48 hours by reducing the FBS to 1% 
in order to synchronize cell population growth prior to treatment.  This procedure was performed 
once in triplicate (n=3). 
Drug Treatment: 
To treat CASMC with the H2S-donating drug, S-diclofenac was dissolved in a vehicle 
containing cell culture medium with 0.5%DMSO, and then degassed with argon to minimize 
spontaneous oxidation of the S-diclofenac.   A final concentration of 50 μM of S-diclofenac was 
added directly to the medium of each designated well for each time point. To serve as a control for 
the effect of H2S alone, cells were treated with 50 μM of sodium sulfide (NaHS), which quickly 
liberates H2S.  Because DMSO is an anti-oxidant capable of affecting gene and protein expression, 
a vehicle control (0.5%DMSO in cell culture medium) was added directly to cells. Media were 
collected on ice into tubes containing proteinase inhibitor at 6h post treatment.  Media were also 
collected from wells containing untreated cells.  Media was stored at -80°C until the ELISA. Cell 
samples were collected on ice at 6 hours post treatment and mixed with Lysis Buffer to lyse the 
cells, forming CASMC lysates.  Cell lysates were stored at -20°C until RNA isolation for 
downstream qPCR applications. HUVECs were treated with NaHS (degassed in argon) to liberate 
H2S. Treatment groups included: 50 μM and 200μM of NaHS, 50 μM Diclofenac which was 
dissolved in a vehicle containing culture medium with 5%DMSO (degassed with argon), and a 
vehicle control (DMSO). Treatments were added directly to the medium of each designated well. 
Media was collected into tubes containing protease inhibitor at 6 hours post treatment and stored 
for ELISA.  Media was also collected from wells containing untreated cells.  
To treat HUVECs in hyperglycemic conditions, cells were cultured in 6 well plates for 3 
days.  Each day cells were treated with fresh media containing either normal glucose (5mM) as a 
control, mannitol (20mM) to control for hyperosmolarity, or high glucose (25mM) to mimic 
chronic hyperglycemia.  After the 3 day period, all cells were treated with varying doses (0, 50, 
100, 150, 200 μM) NaHS for 6 hours. Media were collected in protease inhibitor and stored for 
ELISA. 
Enzyme- Linked Immunosorbent Assay: 
To measure the cytokine PLGF secretion by CASMC and HUVEC, sample media 
harvested from treated cells were added to each well of the Enzyme-Linked Immunosorbent Assay 
(ELISA) plate, which was coated with the capture antibody of interest (PLGF) and incubated for 
2 hours at room temperature. The wells were washed 4X followed by the addition of a detection 
antibody and incubation at room temperature for 2 hours. The detection antibody is linked to 
Streptavidin-HRP, which allows for a colorimetric reaction to occur upon the addition of the 
substrate solution and 20 minute incubation at room temperature. Stop solution was then added to 
each well and the absorbance was measured at 450 nm using a microplate reader. The absorbance 
values were used to calculate the pg/mL of protein (VEGF or PLGF) based upon a standard curve 
generated from known concentrations of the protein of interest that were assayed alongside our 
samples.  
It is important to normalize the secretion (pg/mL) of our protein of interest relative to total 
protein secretion (mg/mL) thereby controlling for any global changes in translation of total protein 
following treatment conditions.  To normalize the cytokine expression data, sample media were 
used in the Bicinchoninic Acid Protein Assay (BCA).  In short, this assay allows for a colorimetric 
reaction to occur that measures the total protein present in samples. The BCA assay relies on two 
reactions. Peptide bonds in protein reduce Cu2+ ions from the cupric sulfate to Cu+. The amount of 
Cu2+ reduced is proportional to the amount of protein present in the solution. Then, two molecules 
of bicinchoninic acid react with each Cu+ ion, forming a purple-colored product that strongly 
absorbs light at a specific wavelength. The bicinchoninic acid Cu+ complex is influenced in protein 
samples by the presence of cysteine, tyrosine, and tryptophan side chains. The amount of protein 
present in a solution can be quantified by measuring the absorption spectra at 540 nm and 
comparing with protein solutions of known concentration using a microplate reader. 
RNA Isolation: 
RNA is isolated from the cell lysates through combining guanidine-isothiocyanate lysis 
with silica-membrane purification.  To isolate RNA from coronary artery muscle cells, ethanol 
was mixed with the lysates to provide ideal binding conditions. Cell lysates were transferred to 
Qiagen columns onto the RNeasy silica membrane. Lysates were washed with RNA Wash Buffer 
once and RPE Wash Buffer, twice and then centrifuged after each wash. The fluid in the collection 
tube was discarded each time.  Then, RNase-free water was added to the column and centrifuged.  
The elution from the collection tube was collected and quantified using a NanoVue reader. These 
RNA samples were stored at -80°C until cDNA synthesis.   
RNA samples were treated with gDNA Wipeout Buffer to remove any genomic DNA 
contaminating the RNA sample to give pure RNA samples. In order for RNA to be converted to 
cDNA, the enzyme reverse transcriptase was added to the RNA sample to reverse transcribe the 
cDNA. This was done by adding a mastermix of Quantiscript RT, Quantiscript RT Buffer, and RT 
Primer Mix to the microtubes and by placing the microtubes of mastermix and RNA sample in the 
G-Storm Cycler for 15 minutes at 42°C then for 3 minutes at 95°C.  The cDNA samples were then 
stored at -20°C until real time qPCR.   
Quantitative PCR: 
 To measure gene expression by coronary artery muscle cells, cDNA samples were added 
to each well of the qPCR plate, which was followed by the addition of a master mix of SYBR 
green, dNTPs, Taq DNA polymerase, MgCl2, UNG, ROX Reference Dye and stabilizers, forward 
primer and reverse primer of the target gene, and molecular grade water. The forward and reverse 
primers specifically bind to the CSE gene sequence within the sample cDNA, and a DNA 
polymerase then synthesizes copies of the primer-specific region of the CSE gene. SYBR green is 
a fluorescent dye which intercalates the DNA as CSE cDNA is amplified. The fluorescence 
increases as SYBR green intercalates the amplified DNA. This increase in fluorescence reflects an 
increase in the gene expression of CSE.  The fluorescent signal was measured using an Eppendorf 
RealPlex, and the delta delta Ct method was used to determine the fold change in gene expression 
relative to the expression of the housekeeping gene, beta actin.  
 
Results  
Overall, the levels of PLGF protein secretion were low in CASMCs in this study. Literature 
indicates that basal PLGF levels are very low in CASMC supporting the low levels of PLGF 
protein secretion found in this study are comparable to PLGF secretion in HUVECs. However, we 
found that PLGF protein secretion decreased in CASMCs treated with S-diclofenac, Vehicle, and 
NaHS compared to the control 6 hours post treatment (Fig. 1). Treatment with the vehicle caused 
the greatest decrease in PLGF secretion, possibly due to the anti-inflammatory properties of the 




Figure 1. S-Diclofenac and NaHS reduced PLGF secretion by coronary artery smooth muscle 
at 6 hours. S-Diclofenac, NaHS, DMSO, and control treated CASMC media was collected at 6h, 
and PLGF protein was quantified. There was a decrease in PLGF secretion by S-Diclofenac and 








































PLGF protein secretion levels in HUVECs were much higher than CASMCs’ PLGF 
protein secretion levels in this study. We found that PLGF protein secretion decreased in HUVECs 
treated with S-diclofenac and 200μM NaHS compared to the control at 6 hours post treatment (Fig. 
2).  There were minor decreases in PLGF secretion in HUVECs treated with the vehicle (DMSO) 
and 50 µM NaHS compared to the control 6 hours post treatment (Fig. 2).  
 
 
Figure 2. 200µM NaHS and S-diclofenac decreased PLGF secretion by human primary 
endothelial cells at 6 hours. Media were collected from HUVEC treated with S-diclofenac, 50µM 
NaHS, 200µM NaHS, DMSO, and control for 6h, and PLGF protein was quantified. There was a 
decrease in PLGF secretion by S-diclofenac and 200µM NaHS treated cells versus control (n=3). 
  
We found that CASMCs treated with S-diclofenac, vehicle, and NaHS 6 hours post 
treatment showed an increase in CSE gene expression compared to the control (Fig. 3).  There was 
no difference between treatment with S-diclofenac and the vehicle used to make up S-diclofenac 
(Fig. 3). Therefore, it was unclear if the large increase in CSE gene expression of cells treated with 
S-diclofenac was due to the anti-inflammatory components of the vehicle or the H2S donating 







































Fig. 3: H2S increases CSE gene expression by coronary artery smooth muscle at 6 hours. 
Cells treated with s-diclofenac, Vehicle, and NaHS 6 hours post treatment showed an increase in 
CSE gene expression compared to the control. There was a substantial increase in CSE gene 
expression for cells treated with S-diclofenac compared to cells treated with NaHS. 
 
Figure 4 is a representation of HUVECs exposed to a diabetic, or hyperosmolar conditions. 
We found that exposure to mannitol and high glucose without NaHS caused an increase in PLGF 
secretion compared to the normal glucose (control) after 3 days (Fig. 4).  We also found that larger 
treatments with NaHS caused a reversal of PLGF secretion by HUVECs exposed to high glucose 
back to PLGF secretion by cells exposed to normal glucose levels (Fig. 4).   
 
 
Figure 4. Chronic hyperosmolar conditions increased PLGF secretion by human endothelial 
cells and this effect was reversed by NaHS. HUVEC were treated with either normal glucose 
































NaHS were added to the HUVEC. Media was collected at 6h, and PLGF protein was quantified. 




Overall, we determined that exposure to H2S reduced PLGF secretion in human vascular 
cells. Based on the literature that demonstrates PLGF is pro-atherogenic the observed decrease in 
PLGF secretion by vascular cells following exposure to H2S shows that H2S potentially exerts an  
anti-atherogenic effect. Decreased PLGF secretion when exposed to H2S suggests a reversal of 
preliminary atherosclerosis, as opposed to having pro-angiogenic properties, as we originally 
hypothesized. The H2S donating drug, S-diclofenac, had inconclusive effects on the vascular cells. 
While a decrease in PLGF secretion was observed in human vascular cells when treated with S-
diclofenac, the S-diclofenac vehicle alonealso caused a decrease in PLGF secretion. The vehicle, 
DMSO, has anti-inflammatory properties, as well. Therefore, it is unclear if the decrease in PLGF 
secretion observed in human vascular cells when treated with S-diclofenac was due to the S-
diclofenac portion or the vehicle portion of the drug. 
Exposure to H2S increased CSE gene expression in CASMCs, suggesting an increase in 
endogenous H2S production. Previous data shows that CSE gene expression is increased in 
coronary ECs following shear stress patterns similar to blood flow in atherosclerotic arteries, 
suggesting CSE is up-regulated to produce the cardioprotective gas, H2S. This increase in CSE 
gene expression in coronary ECs suggests an increase in H2S gas in the vessel wall. When exposed 
to H2S, potentially from coronary ECs, CASMCs increase CSE gene expression to produce H2S, 
as well. Together, these findings suggest that H2S has a potential autocrine effect resulting in a 
positive feedback loop of H2S gas in the vessel wall increasing H2S levels in order to perform its 
anti-atherogenic role. 
In hyperglycemic conditions, mannitol served as the control for hyperosmolarity due to its 
similar osmolarity to glucose. The increase in PLGF secretion after exposure to mannitol suggests 
that the hyperosmolarity alone caused the increase in PLGF secretion after exposure to glucose, 
not the presence of glucose specifically in the media. In hyperglycemic conditions, 
hyperosmolarity substantially increased the secretion of PLGF by human endothelial cells. This 
increase in PLGF secretion suggests early progression of atherosclerosis due to hyperosmolar 
conditions, a risk factor for atherosclerosis. The hyperosmolar-induced increase in PLGF secretion 
was reversed by H2S, suggesting that H2S is a cardioprotective gas against atherosclerosis in both 
basal and hyperglycemic/hyperosmolar conditions. While treated diabetic patients do not usually 
have hyperosmolar plasma, this finding could have possible implications for individuals with 
untreated diabetes who may experience hyperglycemic, hyperosmolar events.  
One limitation of this study is HUVECs were used to better understand the effects that H2S 
had on the endothelial cells of the vessel wall instead of human coronary artery endothelial cells. 
HUVECs were used due to cost, but these cells may not best represent the endothelial vessel lining 
of coronary arteries. To improve this study, human coronary artery endothelial cells may be treated 
with H2S in order to measure PLGF secretion and therefore determine whether our results were 
accurate. Also, there is an insufficient n value for statistical analysis to prove the significance of 
the correlations observed. This experiment needs to be repeated in both basal and hyperglycemic 
conditions to increase the n value for statistical analysis. 
Future studies include increasing our n value to determine statistical significance of this 
observed response to H2S.  Also, further studies are also needed to determine the mechanism 
whereby H2S affects PLGF secretion under basal and hyperosmolar conditions. 
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